KROS Q3 2025 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+3575.8% YoY

Gross Profit

$14M97.2% margin

Operating Income

-$15M-107.9% margin

Net Income

-$7M-51.0% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-21.5%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$743M

Total Liabilities

$39M

Stockholders' Equity

$704M

Cash & Equivalents

$693M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$388,000	+3575.8%
Gross Profit	$14M	$74,000	+18639.2%
Operating Income	-$15M	-$59M	+73.8%
Net Income	-$7M	-$53M	+86.3%

Revenue Segments

License

$10M70%

Service, Other

$4M30%